India · Delayed Price · Currency is INR Navin Fluorine International Earnings Call Transcripts
Fiscal Year 2026
-
Revenue and profitability grew strongly in Q4 and FY26, with all segments contributing to robust results. CapEx projects and new capacities are on track, supporting double-digit growth outlook and strong margins, while risk management and capital discipline remain priorities.
-
Q3 and nine-month FY 2026 saw robust revenue and profit growth, with all business segments delivering strong results and margin expansion. Capacity additions, new project ramp-ups, and disciplined cost control underpin a positive outlook, with ongoing CapEx and policy support fueling future growth.
-
Q2 FY 2026 saw 46% revenue growth and a 129% jump in EBITDA, with all segments performing strongly. Strategic capex in R32 and Specialty Chemicals, robust order book, and improved margins set the stage for continued growth, with FY 2026 EBITDA margin guided at 28-30%.
-
Q1 FY26 delivered 39% revenue growth and 129% net profit growth, with all divisions performing strongly and margins expanding to 28.5%. Strategic projects, robust order book, and expanded CapEx frame support a positive outlook, despite ongoing pricing pressures in agchem.
Fiscal Year 2025
-
Record annual and quarterly revenues were achieved, with strong EBITDA margin expansion and robust growth across all segments. Strategic partnerships in advanced materials and high-purity chemicals, along with disciplined CapEx and margin guidance, position the business for continued growth.
-
Q3 FY25 saw 21% YoY revenue growth and a 95% YoY jump in EBITDA, with margins reaching 24.3%. All segments contributed to growth, major CapEx projects are on track, and order visibility remains strong for FY26, especially in specialty chemicals and CDMO.
-
Q2 FY25 revenue grew 10% year-on-year, led by HPP and CDMO, while Specialty Chemicals saw a 15% decline but is expected to recover in H2. Strong order visibility and ongoing capacity expansions support a positive outlook, with net debt to equity at 0.39.
-
Q1 FY25 saw 7% revenue growth, led by HPP, while specialty and CDMO segments faced headwinds from global inventory rationalization. Multiple CapEx projects are on track, margins are improving sequentially, and the outlook remains positive for the second half of FY25.